MERMAID-2: Phase 3 study of durvalumab in patients with resected, Stage II-III NSCLC who become MRD plus after curative-intent therapyN. Reinmuth, D. Spigel,S. Peters,M. J. Ahn,M. Tsuboi,J. Chaft, D. Harpole, F. Barlesi,C. Abbosh, H. Mann,R. May, P. Dennis,C. SwantonONCOLOGY RESEARCH AND TREATMENT（2021）引用 0|浏览3暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
